We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+6.08%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$42.8B
AUM Growth
+$3.35B
(+8.5%)
Cap. Flow
+$1.35B
Cap. Flow
% of AUM
3.15%
Top 10 Holdings %
Top 10 Hldgs %
14.82%
Holding
2,894
New
39
Increased
2,631
Reduced
168
Closed
44
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$21.8M |
| 2 |
Chevron
CVX
|
+$20.5M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$19.7M |
| 4 |
Incyte
INCY
|
+$17.8M |
| 5 |
ExxonMobil
XOM
|
+$16.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SE
Spectra Energy Corp Wi
SE
|
+$49.6M |
| 2 |
STJ
St Jude Medical
STJ
|
+$41.1M |
| 3 |
LLTC
Linear Technology Corp
LLTC
|
+$30.3M |
| 4 |
HAR
Harman International Industries
HAR
|
+$13.8M |
| 5 |
ENH
Endurance Specialty Holdings Ltd
ENH
|
+$10.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.2% |
| 2 | Technology | 15.06% |
| 3 | Healthcare | 13.05% |
| 4 | Industrials | 10.88% |
| 5 | Consumer Discretionary | 9.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HT
1626
DELISTED
Hersha Hospitality Trust Priority Class A Common Shares of Beneficial Interest
HT
| $1.78M | ﹤0.01% |
94,863
+35,303
| +59% | +$708K |
|
1627
Halozyme
HALO
$9.79B
| $1.78M | ﹤0.01% |
137,360
+8,121
| +6% | +$103K |
|
1628
Sarepta Therapeutics
SRPT
$1.57B
| $1.78M | ﹤0.01% |
60,079
+2,082
| +4% | +$64.4K |
|
1629
Southside Bancshares
SBSI
$967M
| $1.77M | ﹤0.01% |
54,114
+15,516
| +40% | +$531K |
|
1630
Oxford Industries
OXM
$566M
| $1.76M | ﹤0.01% |
30,684
+8,123
| +36% | +$449K |
|
1631
Resources Connection
RGP
$151M
| $1.75M | ﹤0.01% |
104,598
+12,228
| +13% | +$207K |
|
1632
The Ensign Group
ENSG
$10.4B
| $1.75M | ﹤0.01% |
99,482
+27,630
| +38% | +$499K |
|
|
LDL
1633
DELISTED
Lydall, Inc.
LDL
| $1.75M | ﹤0.01% |
32,566
+9,513
| +41% | +$540K |
|
1634
Buckle
BKE
$2.25B
| $1.74M | ﹤0.01% |
93,729
+16,393
| +21% | +$330K |
|
1635
Kearny Financial
KRNY
$604M
| $1.73M | ﹤0.01% |
115,089
+1,446
| +1% | +$21.8K |
|
|
BGC
1636
DELISTED
General Cable Corporation
BGC
| $1.73M | ﹤0.01% |
96,462
+27,438
| +40% | +$492K |
|
1637
CNA Financial
CNA
$14.2B
| $1.73M | ﹤0.01% |
39,156
+12,340
| +46% | +$525K |
|
1638
Koppers
KOP
$943M
| $1.73M | ﹤0.01% |
40,758
+11,627
| +40% | +$488K |
|
1639
Strategic Education
STRA
$1.85B
| $1.73M | ﹤0.01% |
21,449
+5,932
| +38% | +$475K |
|
|
MNTA
1640
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $1.72M | ﹤0.01% |
129,087
+37,076
| +40% | +$581K |
|
|
LHCG
1641
DELISTED
LHC Group LLC
LHCG
| $1.72M | ﹤0.01% |
31,870
+8,238
| +35% | +$400K |
|
1642
LivaNova
LIVN
$4.4B
| $1.7M | ﹤0.01% |
34,692
+735
| +2% | +$35.8K |
|
1643
Griffon
GFF
$3.95B
| $1.7M | ﹤0.01% |
68,833
+17,217
| +33% | +$429K |
|
1644
Interparfums
IPAR
$3.99B
| $1.7M | ﹤0.01% |
46,436
+9,167
| +25% | +$317K |
|
|
INFN
1645
DELISTED
Infinera Corporation Common Stock
INFN
| $1.7M | ﹤0.01% |
165,872
+4,150
| +3% | +$41.6K |
|
1646
Winnebago Industries
WGO
$856M
| $1.7M | ﹤0.01% |
57,978
+15,099
| +35% | +$482K |
|
|
ALX
1647
Alexander's
ALX
$1.3B
| $1.69M | ﹤0.01% |
3,910
+190
| +5% | +$81.2K |
|
|
TWOU
1648
DELISTED
2U Inc
TWOU
| $1.68M | ﹤0.01% |
1,415
+45
| +3% | +$48.1K |
|
1649
Abercrombie & Fitch
ANF
$4.42B
| $1.68M | ﹤0.01% |
140,906
+36,267
| +35% | +$432K |
|
1650
Terreno Realty
TRNO
$7.57B
| $1.68M | ﹤0.01% |
60,033
+4,836
| +9% | +$134K |
|
Similar funds
VAM
RhumbLine Advisers's Q1 2017 Portfolio in Review
As of Q1 2017, RhumbLine Advisers held 2,894 positions worth $42.8B, up 8.5% from $39.5B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
RhumbLine Advisers deployed $1.35B of net new capital in Q1 2017, opening 39 new positions and adding to 2,631 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Biogen, an estimated $8.21M trimmed.
- RhumbLine Advisers's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
- RhumbLine Advisers added most to Abbott in Q1 2017, an estimated $21.8M increase.
- RhumbLine Advisers's biggest Q1 2017 reduction was Biogen, cutting an estimated $8.21M.
- RhumbLine Advisers fully exited Spectra Energy Corp Wi in Q1 2017, selling an estimated $49.6M.
- RhumbLine Advisers's ten largest holdings make up 15% of its $42.8B portfolio in Q1 2017.
- RhumbLine Advisers opened 39 new positions and closed 44 in Q1 2017.
- RhumbLine Advisers's portfolio value rose 8.5% quarter-over-quarter to $42.8B.
Based on RhumbLine Advisers's 13F filing for Q1 2017, filed 2 May 2017.